Pfizer buys Amplyx to grow infectious disease pipeline

Pfizer has bought infectious disease biotech Amplyx Pharmaceuticals for an undisclosed sum. The deal gives Pfizer control of a pipeline led by phase 2 antifungal candidate fosmanogepix.

Amplyx received investment from Pfizer last year as part of a $93 million series C round that set the biotech up to advance fosmanogepix and MAU868, a neutralizing antibody targeting the BK virus. In the months after disclosing the investment, Amplyx shared phase 2 data linking fosmanogepix to an 80% treatment success rate in patients with invasive fungal infections caused by Candida.